Neurocrine Biosciences target price cut to $150 from $164
NBIX•BMO cut its target price for Neurocrine Biosciences to $150 from $164.
Related News
Virtus Investment Partners: TD Cowen cuts target price to $136 from $155
VRTS•
Tradeweb Markets Inc: TD Cowen raises target price to $107 from $98
TW•
Duke Energy target price cut to $130 from $135 by Truist Securities
DUK•
NervGen announces first participant dosed in Phase 3 study of NVG-291
NGEN•
StoneX raises Cantor Equity Partners II target price to $18 from $12
SECZ•